Abdullah Mohammad Arshad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Abdullah Mohammad Arshad has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Fateen Ata
Cleveland Clinic Foundation Ohio USA
2 shared publications - Sundus Sardar
Penn State Health Milton S Hershey Medical Center
2 shared publications - Abdulaziz Zafar
Internal Medicine, Hamad Medical Corporation, Doha, QAT
1 shared publication - Abdullah Shams
Internal Medicine, CMH Lahore Medical and Dental College
1 shared publication - Ahmad Matarneh
Department of Nephrology Penn State Milton S Hershey Medical Center Hershey Pennsylvania USA
1 shared publication Aisha Al Adab
Pulmonology Department, Hamad Medical Corporation, Doha, Qatar
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (2) , 19
Breathless on the journey: Unmasking palbociclib-induced pneumonitis in a geriatric breast cancer warrior
QScience.com is the innovative and collaborative, peer-reviewed, online publishing platform from Hamad bin Khalifa University Press (HBKU Press). It offers a fast and transparent Open Access scholarly publishing process, which is centered on the author, bringing their research to a global audience.
- 1 January 2024
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (2) , 19
Open AccessBreathless on the journey: Unmasking palbociclib-induced pneumonitis in a geriatric breast cancer warrior
QScience.com is the innovative and collaborative, peer-reviewed, online publishing platform from Hamad bin Khalifa University Press (HBKU Press). It offers a fast and transparent Open Access scholarly publishing process, which is centered on the author, bringing their research to a global audience.
- Open Access
- 1 January 2024
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (2) , 5
Tuberculosis imitating malignancy: Unusual presentation as a metastatic tumor – A case report
QScience.com is the innovative and collaborative, peer-reviewed, online publishing platform from Hamad bin Khalifa University Press (HBKU Press). It offers a fast and transparent Open Access scholarly publishing process, which is centered on the author, bringing their research to a global audience.
- 1 January 2024
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (2) , 5
Open AccessTuberculosis imitating malignancy: Unusual presentation as a metastatic tumor – A case report
QScience.com is the innovative and collaborative, peer-reviewed, online publishing platform from Hamad bin Khalifa University Press (HBKU Press). It offers a fast and transparent Open Access scholarly publishing process, which is centered on the author, bringing their research to a global audience.
- Open Access
- 29 July 2022
- Published by Elsevier in Thrombosis Research
- Vol. 217, 86-95
Optimal management, prevalence, and clinical behavior of saddle pulmonary embolism: A systematic review and meta-analysis
- 29 July 2022
- Published by Elsevier in Thrombosis Research
- Vol. 217, 86-95
Open AccessOptimal management, prevalence, and clinical behavior of saddle pulmonary embolism: A systematic review and meta-analysis
- Open Access
- 30 June 2022
- Published by Wiley
Cerebral neuroschistosomiasis presenting as a brain mass. A case report.
Neuroschistosomiasis is a rare entity, it can cause cerebral or spinal cord involvement. high clinical suspicion is needed to diagnose it and rapid treatment is needed to prevent complications.
- 30 June 2022
- Published by Wiley
Open AccessCerebral neuroschistosomiasis presenting as a brain mass. A case report.
Neuroschistosomiasis is a rare entity, it can cause cerebral or spinal cord involvement. high clinical suspicion is needed to diagnose it and rapid treatment is needed to prevent complications.
- Open Access
- 5 September 2021
- Published by Wiley
Efficacy and safety of Bosutinib in Patient with Chronic myeloid leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report
Bosutinib is approved as first line therapy for treatment of chronic phase CML and also in patients who are either resistant or intolerant to previous TKI. We present a 59 year old male who was intolerant to 2 TKI but showed excellent hematological and major molecular response to Bosutinib.
- 5 September 2021
- Published by Wiley
Open AccessEfficacy and safety of Bosutinib in Patient with Chronic myeloid leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report
Bosutinib is approved as first line therapy for treatment of chronic phase CML and also in patients who are either resistant or intolerant to previous TKI. We present a 59 year old male who was intolerant to 2 TKI but showed excellent hematological and major molecular response to Bosutinib.
- Open Access
- 3 April 2021
- Published by Springer Nature in Cureus
- Vol. 13 (4)
Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis
Coronavirus disease 19 (COVID-19) has affected over 180 countries, resulting in global mass death. It has been reported that patients with underlying disease are more likely to contract the disease and become critically ill. The impact of chronic kidney disease (CKD) on the severity of COVID-19 has been underlined in the literature. In this analysis, we have provided evidence of an association between CKD and COVID-19. We followed the PRISMA protocol and conducted a literature search using Google Scholar, EMBASE, PubMed, and Clinical trail.gov. The initial search yielded 2102 articles. We included 20 cohorts based on inclusion criteria reporting an association between CKD and COVID-19 after excluding irrelevant articles, including review articles and duplicates. We conducted pooled prevalence of CKD and meta-analysis to estimate the odds ratio (OR), 95% confidence interval (CI) using Cochrane RevMan (version 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration), and R programming language version 4.16-2 (University of Auckland, New Zealand). Our study involved 4350 patients from different countries, and 212 (4.9%) patients had CKD. Among 20 cohorts, 57.27% were male with a median age of 55.5 years. Eight hundred sixty-six patients developed severe COVID-19, and out of which, 39 (4.5%) were CKD patients. CKD patients had a significantly increased risk of severe disease as compared to non-CKD patients with a pooled OR of 2.15 (95% CI 1.16-4.01) (I2=41; p=0.02). Out of 443 COIVD-19 patients who died, 85 patients had CKD, with a prevalence of 19.18%. CKD patients had an increased risk of death as compared to non-CKD patients with a pooled OR of 5.58 (95% CI 3.27-9.54) (I2=0; p<0.00001). CKD is manifested as a common underlying disease in COVID-19 patients who had a worse prognosis, including mortality.
- 3 April 2021
- Published by Springer Nature in Cureus
- Vol. 13 (4)
Open AccessImpact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis
Coronavirus disease 19 (COVID-19) has affected over 180 countries, resulting in global mass death. It has been reported that patients with underlying disease are more likely to contract the disease and become critically ill. The impact of chronic kidney disease (CKD) on the severity of COVID-19 has been underlined in the literature. In this analysis, we have provided evidence of an association between CKD and COVID-19. We followed the PRISMA protocol and conducted a literature search using Google Scholar, EMBASE, PubMed, and Clinical trail.gov. The initial search yielded 2102 articles. We included 20 cohorts based on inclusion criteria reporting an association between CKD and COVID-19 after excluding irrelevant articles, including review articles and duplicates. We conducted pooled prevalence of CKD and meta-analysis to estimate the odds ratio (OR), 95% confidence interval (CI) using Cochrane RevMan (version 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration), and R programming language version 4.16-2 (University of Auckland, New Zealand). Our study involved 4350 patients from different countries, and 212 (4.9%) patients had CKD. Among 20 cohorts, 57.27% were male with a median age of 55.5 years. Eight hundred sixty-six patients developed severe COVID-19, and out of which, 39 (4.5%) were CKD patients. CKD patients had a significantly increased risk of severe disease as compared to non-CKD patients with a pooled OR of 2.15 (95% CI 1.16-4.01) (I2=41; p=0.02). Out of 443 COIVD-19 patients who died, 85 patients had CKD, with a prevalence of 19.18%. CKD patients had an increased risk of death as compared to non-CKD patients with a pooled OR of 5.58 (95% CI 3.27-9.54) (I2=0; p<0.00001). CKD is manifested as a common underlying disease in COVID-19 patients who had a worse prognosis, including mortality.
- Open Access
- 8 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
Hepatosplenic Bartonellosis in an Immunocompetent Teenager: An Atypical Presentation of Cat-Scratch Disease
Infection with Bartonella henselae, a gram-negative coccobacillus, most frequently presents as cat-scratch disease (CSD) and often accompanies a recent history of cat bite or scratch. As compared to adults, teenagers and children or immunocompromised patients are predominantly affected by CSD. In immunocompetent individuals, CSD is typically a self-limiting clinical syndrome with complete resolution of febrile illness in two to four weeks with or without antimicrobial therapy. While most cases present with fever of unknown origin (FUO), previous reports have also documented atypical clinical presentation or systemic symptoms in few cases, including reports of hepatosplenic involvement. We present a case of visceral bartonellosis in an immunocompetent 15-year-old female, who presented with a six-week history of fever and abdominal pain with hepatosplenomegaly. She recovered completely after prolonged antibiotic treatment for six weeks with doxycycline and amikacin. We emphasize that in the workup of FUO, it may be pertinent to include bartonellosis as a differential especially in cases exhibiting hepatosplenomegaly on examination along with hepatosplenic lesions on imaging.
- 8 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
Open AccessHepatosplenic Bartonellosis in an Immunocompetent Teenager: An Atypical Presentation of Cat-Scratch Disease
Infection with Bartonella henselae, a gram-negative coccobacillus, most frequently presents as cat-scratch disease (CSD) and often accompanies a recent history of cat bite or scratch. As compared to adults, teenagers and children or immunocompromised patients are predominantly affected by CSD. In immunocompetent individuals, CSD is typically a self-limiting clinical syndrome with complete resolution of febrile illness in two to four weeks with or without antimicrobial therapy. While most cases present with fever of unknown origin (FUO), previous reports have also documented atypical clinical presentation or systemic symptoms in few cases, including reports of hepatosplenic involvement. We present a case of visceral bartonellosis in an immunocompetent 15-year-old female, who presented with a six-week history of fever and abdominal pain with hepatosplenomegaly. She recovered completely after prolonged antibiotic treatment for six weeks with doxycycline and amikacin. We emphasize that in the workup of FUO, it may be pertinent to include bartonellosis as a differential especially in cases exhibiting hepatosplenomegaly on examination along with hepatosplenic lesions on imaging.